Literature DB >> 23462713

Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi.

Martine Keenan1, Paul W Alexander, Hugo Diao, Wayne M Best, Andrea Khong, Maria Kerfoot, R C Andrew Thompson, Karen L White, David M Shackleford, Eileen Ryan, Alison D Gregg, Susan A Charman, Thomas W von Geldern, Ivan Scandale, Eric Chatelain.   

Abstract

A scaffold hopping exercise undertaken to expand the structural diversity of the fenarimol series of anti-Trypanosoma cruzi (T. cruzi) compounds led to preparation of simple 1-[phenyl(pyridin-3-yl)methyl]piperazinyl analogues of fenarimol which were investigated for their ability to inhibit T. cruzi in vitro in a whole organism assay. A range of compounds bearing amide, sulfonamide, carbamate/carbonate and aryl moieties exhibited low nM activities and two analogues were further studied for in vivo efficacy in a mouse model of T. cruzi infection. One compound, the citrate salt of 37, was efficacious in a mouse model of acute T. cruzi infection after once daily oral dosing at 20, 50 and 100 mg/kg for 5 days.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23462713     DOI: 10.1016/j.bmc.2013.01.050

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  10 in total

1.  Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity.

Authors:  Tatiana Y Hargrove; Zdzislaw Wawrzak; Paul W Alexander; Jason H Chaplin; Martine Keenan; Susan A Charman; Catherine J Perez; Michael R Waterman; Eric Chatelain; Galina I Lepesheva
Journal:  J Biol Chem       Date:  2013-09-18       Impact factor: 5.157

Review 2.  Drug strategies targeting CYP51 in neglected tropical diseases.

Authors:  Jun Yong Choi; Larissa M Podust; William R Roush
Journal:  Chem Rev       Date:  2014-10-22       Impact factor: 60.622

3.  Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.

Authors:  Debora F Vieira; Jun Yong Choi; Claudia M Calvet; Jair Lage Siqueira-Neto; Jonathan B Johnston; Danielle Kellar; Jiri Gut; Michael D Cameron; James H McKerrow; William R Roush; Larissa M Podust
Journal:  J Med Chem       Date:  2014-11-25       Impact factor: 7.446

4.  In vitro drug susceptibility of two strains of the wildlife trypanosome, Trypanosoma copemani: A comparison with Trypanosoma cruzi.

Authors:  Adriana Botero; Sarah Keatley; Christopher Peacock; R C Andrew Thompson
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2016-12-23       Impact factor: 4.077

5.  Quantitative Structure-Activity Relationships for Structurally Diverse Chemotypes Having Anti-Trypanosoma cruzi Activity.

Authors:  Anacleto S de Souza; Leonardo L G Ferreira; Aldo S de Oliveira; Adriano D Andricopulo
Journal:  Int J Mol Sci       Date:  2019-06-08       Impact factor: 5.923

6.  Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.

Authors:  Martine Keenan; Jason H Chaplin; Paul W Alexander; Michael J Abbott; Wayne M Best; Andrea Khong; Adriana Botero; Catherine Perez; Scott Cornwall; R Andrew Thompson; Karen L White; David M Shackleford; Maria Koltun; Francis C K Chiu; Julia Morizzi; Eileen Ryan; Michael Campbell; Thomas W von Geldern; Ivan Scandale; Eric Chatelain; Susan A Charman
Journal:  J Med Chem       Date:  2013-12-04       Impact factor: 7.446

7.  Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development.

Authors:  Carolina B Moraes; Miriam A Giardini; Hwayoung Kim; Caio H Franco; Adalberto M Araujo-Junior; Sergio Schenkman; Eric Chatelain; Lucio H Freitas-Junior
Journal:  Sci Rep       Date:  2014-04-16       Impact factor: 4.379

8.  4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency.

Authors:  Claudia M Calvet; Debora F Vieira; Jun Yong Choi; Danielle Kellar; Michael D Cameron; Jair Lage Siqueira-Neto; Jiri Gut; Jonathan B Johnston; Li Lin; Susan Khan; James H McKerrow; William R Roush; Larissa M Podust
Journal:  J Med Chem       Date:  2014-08-19       Impact factor: 7.446

9.  Addressing the most neglected diseases through an open research model: The discovery of fenarimols as novel drug candidates for eumycetoma.

Authors:  Wilson Lim; Youri Melse; Mickey Konings; Hung Phat Duong; Kimberly Eadie; Benoît Laleu; Benjamin Perry; Matthew H Todd; Jean-Robert Ioset; Wendy W J van de Sande
Journal:  PLoS Negl Trop Dis       Date:  2018-04-26

Review 10.  Parasite zoonoses and wildlife: One Health, spillover and human activity.

Authors:  R C Andrew Thompson
Journal:  Int J Parasitol       Date:  2013-07-23       Impact factor: 3.981

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.